Regentis Biomaterials Ltd.
RGNTNYSEAMERICANHealthcareMedical Devices

About Regentis Biomaterials

Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions in the United States. The company offers orthopedic treatments using Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. It offers Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.

Company Information

CEOEli Hazum
Founded2004
IPO DateDecember 4, 2025
CountryIsrael
Fiscal YearJanuary - December

Stock Details

ExchangeNYSEAMERICAN (NYSEAMERICAN)
CurrencyUSD - USD
TypeStock

Contact Information

Phone972 9 960 1917
Address
60 Medinat Hayehudim, Entrance C Herzliya, 4676652 Israel

Corporate Identifiers

CIK0001912966
CUSIP001219096
ISINIL0012190968
SIC2834

Leadership Team & Key Executives

Dr. Ehud Geller
Director, Chairman
Mr. Jeff Dykan
Director
Mr. Keith Valentine
Director(1)
Dr. Eli Hazum
Chief Executive Officer
Mr. Arie ‌ Gordashnikov
Chief Financial Officer